From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications

EJNMMI Research

Table 4 AD to selected target organs for the [¹⁷⁷Lu]Lu-1C1m-Fc 1 DOTA and 3 DOTA

[¹⁷⁷Lu]Lu-1C1m-Fc (average) Absorbed dose (Gy/GBq)
Target organ	M1		M2		M3		M4
Target organ	1 DOTA	3 DOTA	1 DOTA	3 DOTA	1 DOTA	3 DOTA	1 DOTA	3 DOTA
Heart wall	0.37	0.23	0.36	0.15	0.89	0.58	0.59	0.35
Kidneys	1.09	0.66	0.30	0.19	1.48	1.28	0.41	0.34
Liver	1.30	1.79	0.51	0.68	1.27	1.79	0.50	0.70
Lungs	0.11	0.08	0.19	0.16	0.22	0.17	0.41	0.35
Ovaries	3.63	1.88	0.30	0.11	4.63	3.47	0.40	0.11
Red marrow	0.19	0.19	0.35	0.21	0.21	0.37	0.43	0.39
Spleen	0.72	0.73	0.30	0.35	1.35	0.74	0.39	0.35
Uterus	3.13	1.88	0.69	0.64	3.13	0.64	0.73	0.11
Total body	0.15	0.14	0.15	0.14	0.15	0.14	0.15	0.14
E (Sv/GBq)	0.27	0.26	0.18	0.18	0.34	0.36	0.22	0.22

The table reports average AD and the effective dose for the gender averaged human adult model obtained with the OLINDA/EXM 2.1 software for each tested dosimetry methods (M1-M4), for the [¹⁷⁷Lu]Lu-1C1m-Fc 1 DOTA and 3 DOTA